Back to News
Market Impact: 0.2
BioVie To Present Phase 2 ADDRESS-LC Topline Data On Bezisterim's Potential In Long COVID; Today
Source: Nasdaq
Healthcare & Biotech
BioVie Inc. will host a conference call and webcast on September 15, 2026, at 8:30 a.m. ET to discuss topline results from its Phase 2 ADDRESS-LC trial of Bezisterim. The announcement provides no clinical efficacy, safety, or financial results ahead of the event.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
BIVI0.15
More News
- Illumina CEO on Q3 Results and Business Outlook
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Swiss Firms Plan Investment Boost in China Drug, Finance Sectors
- Bernstein SocGen raises Eli Lilly stock price target on strong Q3 beat
- Freedom Broker raises Eli Lilly stock price target on GLP-1 demand
- Regeneron Q3 revenue tops estimates on Sanofi Dupixent profit; shares rise 4%